| 247.98 -5.87 (-2.31%) | 07-15 13:50 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 314.69 | 1-year : | 367.56 |
| Resists | First : | 269.42 | Second : | 314.69 |
| Pivot price | 255.89 |
|||
| Supports | First : | 243.51 | Second : | 227.5 |
| MAs | MA(5) : | 255.68 |
MA(20) : | 250.32 |
| MA(100) : | 237.18 |
MA(250) : | 210.34 |
|
| MACD | MACD : | 5.8 |
Signal : | 6.7 |
| %K %D | K(14,3) : | 55.6 |
D(3) : | 64.7 |
| RSI | RSI(14): 52.4 |
|||
| 52-week | High : | 269.42 | Low : | 158.34 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ JNJ ] has closed above bottom band by 30.4%. Bollinger Bands are 48.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 257.12 - 258.54 | 258.54 - 259.7 |
| Low: | 247.69 - 249.73 | 249.73 - 251.38 |
| Close: | 250.85 - 253.88 | 253.88 - 256.33 |
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Wed, 15 Jul 2026
Johnson & Johnson CFO Says Guidance Hike Is Just the Start - Barron's
Wed, 15 Jul 2026
Johnson unveils $95 billion plan for Iran war, election grants and farm aid - CNN
Wed, 15 Jul 2026
Stevie Johnson surprised by Keon Coleman: Third-year Bills WR is 'locked in,' not immature - NFL.com
Wed, 15 Jul 2026
J&J quarterly earnings beat Wall Street estimates on strength of medicines unit - CNBC
Wed, 15 Jul 2026
Joe slams Speaker Johnson over deadly ICE shootings - MS NOW
Wed, 15 Jul 2026
Mayor Johnson's controversial plan to crack down on ICE agents now faces City Council scrutiny - WBEZ Chicago
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,410 (M) |
| Shares Float | 2,400 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 76.8 (%) |
| Shares Short | 26,580 (K) |
| Shares Short P.Month | 23,410 (K) |
| EPS | 8.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 33.74 |
| Profit Margin | 21.8 % |
| Operating Margin | 27.4 % |
| Return on Assets (ttm) | 8.4 % |
| Return on Equity (ttm) | 26.4 % |
| Qtrly Rev. Growth | 9.8 % |
| Gross Profit (p.s.) | 27.2 |
| Sales Per Share | 39.98 |
| EBITDA (p.s.) | 14.24 |
| Qtrly Earnings Growth | -53 % |
| Operating Cash Flow | 22,870 (M) |
| Levered Free Cash Flow | 12,510 (M) |
| PE Ratio | 29.05 |
| PEG Ratio | 5 |
| Price to Book value | 7.43 |
| Price to Sales | 6.27 |
| Price to Cash Flow | 26.42 |
| Dividend | 1.34 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|